In follow-up experiments with HAP1 cells and different cancer cells, we found that TRPM7 regulates the expression of HER2 and that this regulatory mechanism can be exploited for combinatorial pharmacological treatment of HER2-expressing breast cancer cells. Here, TRPM7 is linked to breast carcinoma.